Merz Aesthetics has won FDA clearance for Ultherapy PRIME to treat skin laxity on the knees, marking the first body-area expansion for the focused ultrasound platform beyond the face and neck. The indication capitalizes on growing demand for non-invasive body contouring and tightening, particularly among patients seeking alternatives to surgical intervention or complementary treatments alongside GLP-1 therapy.
Devices & Tech
Merz Ultherapy PRIME Clears FDA for Knee Skin Laxity
Merz's ultrasound device now cleared for knees. A new body indication in a growing market.
Ultherapy PRIME expands beyond face and neck into knee skin tightening.
Knee laxity remains an underserved aesthetic concern—most practices lack a proven, FDA-cleared modality specifically marketed for the area. Ultherapy PRIME's clearance fills that gap and positions Merz to capture market share in a segment where RF microneedling and radiofrequency devices currently dominate. The clinical data supporting the indication will be critical to your patient education and case selection. Practices already operating Ultherapy systems should evaluate protocol training and pricing strategy for this new revenue stream.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.